News from Preempt.
The evidence, the featured disease, and the coalition — what is moving in risk-based cancer prevention, and why it matters for you.
Risk-based screening: the evidence is in.
The WISDOM trial found that screening guided by personal risk — rather than a fixed annual schedule — reduced advanced-stage (2B) breast cancers by roughly a third. It is the clearest signal yet that knowing your risk first changes outcomes.
Ask what this means for youLatest from Preempt.
The WISDOM trial: risk-based screening cuts advanced breast cancer
Screening guided by personal risk reduced advanced-stage (2B) breast cancers by roughly one third versus a fixed annual schedule.
Featured this month: Early-Onset Colorectal Cancer
The featured-disease collection brings together PatientResource guides, NCCN guidelines, and talks on the early-onset shift.
37.8% of new cancers are linked to modifiable risk
A WHO and IARC analysis finds more than a third of new cancer cases trace to factors we can change — led by tobacco, infection, and alcohol.
Institutions and employers are signing the Declaration
Research institutions, non-profits and employers are joining the Cancer Alliance — a shared commitment to risk-based prevention.
Vaccination and the infection-cancer gap
Infectious agents cause 10.2% of cancers globally. HPV and Hepatitis B vaccination closes much of that preventable gap.
Kicking Cancer's Ass — for people living with cancer
The podcast that meets people where they are — warm, direct, real — as part of whole-person support through a diagnosis.
The science is moving. So can you.
Take a question straight to Preempt — or sign the Cancer Alliance Declaration.